Enliven's price target lowered to $27 from $36 by JonesResearch

From Yahoo Finance: 2025-05-17 12:40:00

JonesResearch analyst Soumit Roy lowered Enliven’s (ELVN) price target to $27 from $36 but maintains a Buy rating. ELVN-001 from Phase 1 late line chronic myeloid leukemia trial showed efficacy and safety inline with expectations. Despite this, the market reacted negatively, treating the stock with a sell-on-news approach. Jones predicts ELVN-001 will perform similarly to Novartis’ Scemblix.



Read more at Yahoo Finance: Enliven price target lowered to $27 from $36 at JonesResearch